Abstract Our multidisciplinary and highly collaborative consortium has been identifying gene variants that are associated with increased vulnerability to compulsive oxycodone use, tolerance to the analgesic effects of oxycodone, and development of withdrawal-induced hyperalgesia by performing the first GWAS using an advanced model of chronic intravenous oxycodone self-administration. We have also created the first preclinical oxycodone biobank which enables researchers who do not have the resources to perform chronic intravenous self-administration or next-generation genome sequencing to perform advanced genetic, molecular, and cellular studies to further our understanding of the biological changes underlying addiction-like behaviors. However, we are facing significant challenges that threaten the viability of this project due to rising labor and supply costs and the need for additional data curation efforts due to equipment/software failures. The overall goal of the following two aims for this 12- month supplement is to ensure the viability of the oxycodone biobank and provide an in-depth analysis and curation of oxycodone addiction-like behaviors. This will address the increased costs of maintaining the repository and the need for accurate and reliable data processing. In Specific Aim 1, we will ensure the continued viability and expansion of the Oxycodone Biobank, which has become an invaluable resource for addiction research. The rising costs of supplies, labor, and equipment maintenance threaten the sustainability of the biobank, and this aim will focus on repairing and updating critical equipment, procuring essential supplies, and covering the increased costs associated with maintaining the repository, including accommodating the increased number of samples. In Specific Aim2, we will reanalyze the entire dataset affected by the MedAssociates software errors. This will involve manually handling the raw data to recover accurate information and processing it into our database. We will employ rigorous data curation protocols to ensure the integrity and accuracy of our findings. This process will include systematic error-checking, data validation, and meticulous integration of corrected data. By maintaining high standards of data curation, we will guarantee the reliability of our analysis and interpretation, providing robust insights into oxycodone addiction-like behaviors. Integrating these curated data with existing behavioral and genetic data, we aim to uncover novel insights into the mechanisms underlying oxycodone addiction and develop more targeted interventions.